[go: up one dir, main page]

NI201800139A - Formulación farmacéutica líquida estable - Google Patents

Formulación farmacéutica líquida estable

Info

Publication number
NI201800139A
NI201800139A NI201800139A NI201800139A NI201800139A NI 201800139 A NI201800139 A NI 201800139A NI 201800139 A NI201800139 A NI 201800139A NI 201800139 A NI201800139 A NI 201800139A NI 201800139 A NI201800139 A NI 201800139A
Authority
NI
Nicaragua
Prior art keywords
stable liquid
pharmulation
formulation
antibody
pharmaceutical formulation
Prior art date
Application number
NI201800139A
Other languages
English (en)
Inventor
Won Lee Joon
Yong Han Won
Jung Kim Su
Seok Oh Jun
Young Kim So
Hyeon Hong Su
Kyeong Shin Yeon
Original Assignee
Celltrion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60787364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201800139(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltrion Inc filed Critical Celltrion Inc
Publication of NI201800139A publication Critical patent/NI201800139A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La presente invención proporciona una formulación farmacéutica líquida estable que contiene: un anticuerpo o su fragmento de unión a antígeno; un tensioactivo; un azúcar o su derivado; y un tampón. La formulación farmacéutica líquida estable de acuerdo con la presente invención tiene baja viscosidad a la vez que contiene un contenido elevado del anticuerpo, tiene una estabilidad durante el almacenamiento a largo plazo excelente basándose en la estabilidad en condiciones aceleradas y condiciones severas, y se puede administrar por vía subcutánea.
NI201800139A 2016-06-30 2018-12-18 Formulación farmacéutica líquida estable NI201800139A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20160083039 2016-06-30

Publications (1)

Publication Number Publication Date
NI201800139A true NI201800139A (es) 2019-03-25

Family

ID=60787364

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201800139A NI201800139A (es) 2016-06-30 2018-12-18 Formulación farmacéutica líquida estable

Country Status (40)

Country Link
US (3) US11951207B2 (es)
EP (2) EP3479819B1 (es)
JP (2) JP7082070B2 (es)
KR (3) KR20180003452A (es)
CN (1) CN109310628A (es)
AU (2) AU2017287743C1 (es)
CA (1) CA3028238C (es)
CL (1) CL2018003662A1 (es)
CO (1) CO2018013689A2 (es)
CR (1) CR20180599A (es)
CU (1) CU24561B1 (es)
DK (1) DK3479819T5 (es)
DO (1) DOP2018000290A (es)
EA (1) EA201892653A1 (es)
EC (1) ECSP18093651A (es)
ES (1) ES2975782T3 (es)
FI (1) FI3479819T3 (es)
GE (1) GEP20217249B (es)
HR (1) HRP20240426T1 (es)
HU (1) HUE066142T2 (es)
IL (1) IL263630B2 (es)
JO (1) JOP20180125B1 (es)
LT (1) LT3479819T (es)
MA (1) MA45562B1 (es)
MD (1) MD3479819T2 (es)
MX (1) MX2018015960A (es)
NI (1) NI201800139A (es)
PE (1) PE20190448A1 (es)
PH (1) PH12018502670B1 (es)
PL (1) PL3479819T3 (es)
PT (1) PT3479819T (es)
RS (1) RS65395B1 (es)
SG (1) SG11201811320YA (es)
SI (1) SI3479819T1 (es)
SM (1) SMT202400143T1 (es)
TN (1) TN2018000443A1 (es)
TW (1) TWI736643B (es)
UA (1) UA122610C2 (es)
WO (1) WO2018004260A1 (es)
ZA (1) ZA201808476B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA3049857A1 (en) 2017-01-11 2018-07-19 Celltrion Inc. Stable liquid formulation
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
WO2020060192A1 (ko) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 고농도의 계면활성제를 포함하는 트라스투주맙 안정화 액체 제제
JP7374544B2 (ja) * 2018-10-10 2023-11-07 アステラス製薬株式会社 標識部－抗ヒト抗体Ｆａｂフラグメント複合体を含む医薬組成物
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
AR118191A1 (es) * 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
CN111686247B (zh) * 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 包含人白介素-4受体α的抗体的液体组合物
WO2020187760A1 (en) * 2019-03-18 2020-09-24 Alvotech Hf Aqueous formulations of tnf-alpha antibodies in high concentrations
WO2020219681A1 (en) * 2019-04-23 2020-10-29 Sanofi Anti-cd38 antibodies and formulations
CN110095615A (zh) * 2019-05-27 2019-08-06 山东艾科达生物科技有限公司 一种测定超敏c反应蛋白含量的试剂盒
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
CA3169901A1 (en) * 2020-03-13 2021-09-16 Mi Gyeong Kim Pharmaceutical liquid composition having increased stability
JP7560038B2 (ja) * 2020-04-06 2024-10-02 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗体製剤
CA3183934A1 (en) * 2020-05-29 2021-12-02 Amgen Inc. Antibody formulations and uses thereof
CN114099424B (zh) * 2020-08-25 2025-03-14 越海百奥药业(绍兴)有限公司 一种重组免疫细胞因子的制剂
KR20240073051A (ko) * 2021-09-16 2024-05-24 주식회사 에이프로젠 항-TNFα 항체를 포함하는 약제학적 조성물
CN113940997B (zh) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 一种双特异性抗体的稳定制剂
CN118369117A (zh) * 2021-12-28 2024-07-19 山东先声生物制药有限公司 一种抗tnfr2抗体药物组合物
CN120322247A (zh) * 2022-12-09 2025-07-15 辛特里亚公司 用TNFα抗体治疗结节病的方法以及相关组合物和方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861335A (en) 1985-07-26 1989-08-29 Duoject Medical Systems Inc. Syringe
US5085642A (en) 1989-07-17 1992-02-04 Survival Technology, Inc. Conveniently carried frequent use autoinjector
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
WO1994011041A1 (en) 1992-11-19 1994-05-26 R G S.A.S. Di Rosaria Galli & C. Disposable auto-injector for prefilled syringes
DE4438360C2 (de) 1994-10-27 1999-05-20 Schott Glas Vorfüllbare partikelarme, sterile Einmalspritze für die Injektion von Präparaten und Verfahren zu ihrer Herstellung
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200710109B (en) * 2005-06-07 2009-10-28 Esbatech Ag Stable and soluble antibodies inhibiting TNFALPHA
KR102013220B1 (ko) 2008-06-25 2019-08-23 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
CN102458469B (zh) * 2009-05-04 2014-12-24 艾伯维生物技术有限公司 人抗TNF-α抗体的稳定高蛋白质浓度制剂
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP2807190B1 (en) * 2012-01-23 2018-12-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ang2 antibodies
MX370199B (es) * 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
NZ629261A (en) 2012-03-07 2017-08-25 Cadila Healthcare Ltd Pharmaceutical formulations of tnf-alpha antibodies
EP2863951A1 (en) 2012-06-12 2015-04-29 Boehringer Ingelheim International GmbH Pharmaceutical formulation for a therapeutic antibody
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
SMT202000147T1 (it) 2012-09-07 2020-05-08 Coherus Biosciences Inc Formulazioni acquose stabili di adalimumab
FR2995214B1 (fr) 2012-09-10 2014-11-21 Adocia Solution a viscosite reduite de proteine a concentration elevee
WO2014058389A1 (en) * 2012-10-12 2014-04-17 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
AU2013334740A1 (en) * 2012-10-25 2015-04-02 Medimmune, Llc Stable, low viscosity antibody formulation
WO2014078866A2 (en) * 2012-11-19 2014-05-22 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
RU2015130100A (ru) 2013-01-24 2017-03-03 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед TNF-альфа антиген-связывающие белки
CA2926588C (en) 2013-10-16 2020-07-21 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
CN104666242B (zh) * 2013-11-26 2018-01-02 信达生物制药(苏州)有限公司 一种稳定的抗TNF‑α抗体制剂及其用途
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
WO2015151115A1 (en) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
ES2600488T3 (es) * 2014-05-23 2017-02-09 Ares Trading S.A. Composición farmacéutica líquida
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
WO2016103093A1 (en) 2014-12-23 2016-06-30 Pfizer Inc. Stable aqueous antibody formulation for anti tnf alpha antibodies
CA2976298A1 (en) 2015-02-13 2016-08-18 Sanofi Stable liquid formulation for monoclonal antibodies
AR118191A1 (es) 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa

Also Published As

Publication number Publication date
LT3479819T (lt) 2024-04-25
NZ770076A (en) 2025-03-28
JOP20180125B1 (ar) 2022-09-15
KR102397713B1 (ko) 2022-05-13
US11951207B2 (en) 2024-04-09
CR20180599A (es) 2019-04-09
IL263630A (en) 2019-01-31
NZ748101A (en) 2020-11-27
AU2020201249A1 (en) 2020-03-12
EP3479819A4 (en) 2020-02-26
MA45562B1 (fr) 2024-05-31
DOP2018000290A (es) 2019-02-15
JOP20180125A1 (ar) 2019-01-30
EP4338752A2 (en) 2024-03-20
CA3028238A1 (en) 2018-01-04
JP2022122941A (ja) 2022-08-23
CL2018003662A1 (es) 2019-03-15
AU2017287743C1 (en) 2020-10-01
CA3028238C (en) 2024-01-02
TWI736643B (zh) 2021-08-21
PT3479819T (pt) 2024-04-15
JP7082070B2 (ja) 2022-06-07
KR20180003452A (ko) 2018-01-09
MA45562A (fr) 2019-05-08
SG11201811320YA (en) 2019-01-30
PH12018502670A1 (en) 2019-10-07
EP3479819A1 (en) 2019-05-08
EP3479819B1 (en) 2024-01-24
KR20210042052A (ko) 2021-04-16
DK3479819T5 (da) 2024-09-09
JP7405324B2 (ja) 2023-12-26
WO2018004260A1 (ko) 2018-01-04
MD3479819T2 (ro) 2024-07-31
PE20190448A1 (es) 2019-03-29
SI3479819T1 (sl) 2024-06-28
ZA201808476B (en) 2020-08-26
FI3479819T3 (fi) 2024-04-17
KR20180097471A (ko) 2018-08-31
MX2018015960A (es) 2019-03-21
AU2017287743A1 (en) 2018-11-22
SMT202400143T1 (it) 2024-05-14
HUE066142T2 (hu) 2024-07-28
UA122610C2 (uk) 2020-12-10
AU2020201249B2 (en) 2021-07-15
PH12018502670B1 (en) 2023-03-24
CO2018013689A2 (es) 2019-01-18
EA201892653A1 (ru) 2019-05-31
GEP20217249B (en) 2021-04-26
TW201806617A (zh) 2018-03-01
US20240269071A1 (en) 2024-08-15
US20240269069A1 (en) 2024-08-15
BR112018076377A2 (pt) 2019-03-26
KR102229274B1 (ko) 2021-03-18
CU20180154A7 (es) 2019-08-06
ES2975782T3 (es) 2024-07-15
CN109310628A (zh) 2019-02-05
US20210000743A1 (en) 2021-01-07
ECSP18093651A (es) 2019-01-31
TN2018000443A1 (en) 2020-06-15
IL263630B2 (en) 2023-06-01
CU24561B1 (es) 2022-01-13
EP4338752A3 (en) 2024-04-03
PL3479819T3 (pl) 2024-07-01
DK3479819T3 (da) 2024-04-15
RS65395B1 (sr) 2024-04-30
AU2017287743B2 (en) 2020-01-30
HRP20240426T1 (hr) 2024-06-21
JP2019525902A (ja) 2019-09-12

Similar Documents

Publication Publication Date Title
NI201800139A (es) Formulación farmacéutica líquida estable
MX382917B (es) Formulaciones de proteínas líquidas que contienen líquidos iónicos.
MX391067B (es) Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
CO2019003630A2 (es) Composiciones no proteínicas de toxina clostridial
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
AR098168A1 (es) Formulación estable de insulina glulisina
BR112018005349A2 (pt) preparação farmacêutica de anticorpo anti-pd-1 estável e sua aplicação em medicamentos
CO7111300A2 (es) Formulación de anticuerpos
MX2015012737A (es) Vacunas de virus bovino liquidas estables.
PE20150190A1 (es) Formulacion farmaceutica
AR103243A1 (es) Recipiente precargado con toxina botulínica
MX2022013947A (es) Formulacion de resiniferatoxina.
EA201700019A1 (ru) Высокочистый оритаванцин и способ его получения
EA201691132A1 (ru) Инъекционное средство и способ образования депо
CO2018002428A2 (es) Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol
CL2018002200A1 (es) Administración combinada de un agente de penetración y un compuesto de azufre que contiene compuesto para las plantas.
MY194758A (en) Stable liquid pharmaceutical formulation
PE20191462A1 (es) Composicion liquida que contiene pradofloxacina
EA201691206A1 (ru) Ноотропное средство "пантокальцин" в жидкой форме
AR113874A1 (es) Terapias de combinación de inhibidor ezh2
HK1226323A1 (en) Liquid protein formulations containing ionic liquids
UA97716U (uk) Лікарський засіб у формі сиропу, що містить фенспіриду гідрохлорид
HK1226318A1 (en) Liquid protein formulations containing organophosphates